Tirzepatide 10mg

Performance Profile

• Dual GLP-1/GIP Receptor Agonism: Activates both GLP-1 and GIP receptors at once — what makes it distinct from single-receptor compounds like Semaglutide. Studied for how hitting two incretin receptors simultaneously changes metabolic outcomes.
• Glycaemic Regulation: Demonstrates significant HbA1c reduction and insulin sensitivity modulation in glucose homeostasis and metabolic dysfunction research models.
• Central Appetite Research: Studied for activity at brain-based appetite centres — provides a useful model for understanding how the central nervous system responds to dual incretin receptor activation.
• Hepatic & Adipose Research: Investigated in liver fat accumulation and adipose biology models. 2026 clinical data makes it a well-characterised reference compound for dual incretin research.

Quick Summary

• Best For: Dual GLP-1/GIP receptor research, comparative incretin studies, glucose homeostasis models.
• Use Case: Investigating how activating two incretin receptors at once changes outcomes relative to single-pathway GLP-1 compounds.
• Research Context: The active compound in Mounjaro and Zepbound — extensive real-world clinical data makes it highly useful as a research reference compound.

For research purposes only. Not for human consumption. For use by licensed researchers only. These compounds have not been evaluated or approved by Health Canada for human use.